lovastatin has been researched along with Hyperlipemia in 237 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (9.28) | 18.7374 |
| 1990's | 139 (58.65) | 18.2507 |
| 2000's | 56 (23.63) | 29.6817 |
| 2010's | 18 (7.59) | 24.3611 |
| 2020's | 2 (0.84) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, R; Sharma, M; Tiwari, M | 1 |
| Kumar, M; Modukuri, RK; Puri, A; Sashidhara, KV; Srivastava, A | 1 |
| Benjian, C; Danping, XU; Huanlin, WU; Huiting, P; Xiaodan, H; Yishi, LI; Yongtao, C | 1 |
| Cicero, AFG; Fogacci, F; Stoian, AP; Toth, PP | 1 |
| Aa, JY; Feng, D; Ge, C; Sun, JG; Tan, ZY; Wang, GJ; Xie, Y; Yan, CX; Yao, L | 1 |
| Chen, JL; Lien, AS; Lin, CH; Wang, TJ; Yang, SH; Yang, YS | 1 |
| da Silva, LCN; de Barros Gomes, E; de Miranda, RCM; Dias, LRL; Neto, RNM; Weba-Soares, L | 1 |
| Aggarwal, G; Arora, R; Goyal, U | 1 |
| Chen, Q; Dai, XY; Deng, LL; Liu, YH; Ying, HZ; Yu, CH; Zang, JN | 1 |
| Cao, J; Fu, X; Li, L; You, J; Zhang, Y | 1 |
| Chen, L; Liang, SF; Shu, GY; Wang, WM; Wei, LX; Wu, JB; Zhang, XH | 1 |
| Bradaric, M; Habis, M; Ismail, N; Lengyel, E; Litchfield, L; Romero, IL; Wroblewski, K; Yamada, SD | 1 |
| Bi, KS; Ding, LL; Li, JM; Li, ZY; Wang, ZT; Xu, BL; Yang, L | 1 |
| Chen, Y; Feng, R; Fu, J; Gao, X; Guo, F; He, CY; Huang, M; Jiang, JD; Li, XY; Luo, SH; Ma, C; Ren, L; Shou, JW; Wang, Y; Wen, BY; Zhao, ZX | 1 |
| Zhou, D; Zhou, J | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Ai, M; Asztalos, BF; Barrett, PH; Buchsbaum, A; Diffenderfer, MR; Dolnikowski, GG; Horvath, KV; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Nyaku, M; Otokozawa, S; Schaefer, EJ | 1 |
| Pyo, YH; Seong, KS | 1 |
| Kuo, TF; Lee, CL; Pan, TM; Wang, JJ; Wu, CL | 1 |
| Buers, I; Engel, T; Hofnagel, O; Robenek, H; Severs, NJ | 1 |
| Bi, CW; Bi, K; Chen, X; Choi, RC; Dong, TT; Li, J; Ran, W; Tsim, KW; Wang, T | 1 |
| Jin, YR; Li, XW; Qu, SC; Sui, DY; Yu, XF; Zhao, XZ | 1 |
| Chen, CL; Pan, TM | 1 |
| Bedford, D; Caslake, MJ; Forster, LF; Packard, CJ; Rogers, E; Shepherd, J; Stewart, G; Stewart, JP | 1 |
| Irons, BK; MacLaughlin, EJ; McCall, K; Snella, KA; Villarreal, M | 1 |
| Mehta, JL; Singh, BK | 1 |
| Kashyap, ML; Moon, YS | 1 |
| Chong, PH; Yim, BT | 1 |
| Li, Y; Sun, M; Yan, W | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Clark, LT | 1 |
| Brazg, R; Hunninghake, DB; Koren, M; McGovern, ME; Murdock, D; Pearson, T; Weiss, S | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Alvarez, E; Amor, A; Castaño, G; Fernández, JL; González, RL; Lezcay, M; Más, R; Menéndez, R | 1 |
| Boden, WE | 1 |
| Connelly, PW; de Souza, R; Emam, A; Faulkner, DA; Jenkins, DJ; Josse, RG; Kendall, CW; Lapsley, KG; Leiter, LA; Marchie, A; Parker, TL; Trautwein, EA; Vidgen, E; Wong, JM | 1 |
| Csonka, C; Csont, T; Ferdinandy, P; Giricz, Z; Onody, A | 1 |
| Thompson, PD | 1 |
| Bays, HE; McGovern, ME | 1 |
| Johnson, R; Manfredi, F; Ormiston, T; Reus, VI; Wolkowitz, OM | 1 |
| Rubenfire, M | 1 |
| Hemwall, EL; Irvin, JD; Levine, JG; Levy, SJ; Melin, JM; Midgette, P; Petrohoy, TM; Reynolds, JM; Struble, WE; Tipping, RW; Vassil, TC | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Connelly, PW; de Souza, R; Emam, A; Faulkner, DA; Jenkins, DJ; Josse, RG; Kendall, CW; Lapsley, KG; Leiter, LA; Marchie, A; Parker, TL; Singer, W; Trautwein, EA; Vidgen, E; Wong, JM | 1 |
| Gao, Y; Li, C; Li, M; Liu, Z; Shi, W | 1 |
| Chang, WC; Chiang, SY; Hsu, YM; Hung, JS; Wu, CH; Yin, PL; Yu, YM | 1 |
| Cheng, XM; Ding, H; Sun, X; Wei, XB; Wu, CX | 1 |
| Chan, YH; Lim, SC; Sum, CF; Tavintharan, S | 1 |
| Kritchevsky, D; Li, C; Wang, Y; Wei, W | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Fears, R | 1 |
| Chisholm, A; Crooke, M; Jackson, R; Mann, J; Neutze, J; North, D; Swinburn, B; White, H; Wilcox, J | 1 |
| Miroshnichenko, NG; Neverov, NI; Stavrovskaia, EV; Tareeva, IE | 1 |
| Ravnskov, U | 1 |
| Jacobson, TA | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Montemartini, C; Perani, G; Raddato, V; Regazzi, MB; Viganò, M | 1 |
| Achacoso, R; Bledsoe, R; Rindone, JP | 1 |
| Boumendil, E; Tubert-Bitter, P | 1 |
| Abdalla, AH; al-Hawas, FA; al-Khader, AA; al-Sulaiman, MH; Mousa, DH; Rassoul, Z; Rehman, MA | 1 |
| Durrington, PN | 1 |
| Hewett, JE; Lal, SM; Petroski, GF; Ross, G; Van Stone, JC | 1 |
| Aguilar-Salinas, CA; Barrett, PH; Delmez, J; Kelber, J; Schonfeld, G | 1 |
| Bahner, U; Heidland, A; Paczek, L; Schaefer, L; Schaefer, RM; Teschner, M | 1 |
| Boumendil, EF | 1 |
| Alcala, J; Blanco, J; Espino, A; Hidalgo, L; Jansen, S; Jiménez-Perepérez, JA; López-Miranda, J; Pérez-Jiménez, F; Prada, JL; Rodríguez, M | 1 |
| Shepherd, J | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Alaupovic, P; Dudley, VS; Knight-Gibson, C; Lane, DM; Laughlin, LO | 1 |
| Caterson, RJ; Ibels, LS; Mahony, JF; Ong, CS; Pollock, CA; Waugh, DA | 2 |
| Dabpetch, O; Jeamanukoolkit, N; Kakong, P; Koanantakul, B; Nontakanun, S; Yipintsoi, S | 1 |
| Castelluccio, A; Fiorini, F; Patrone, E | 1 |
| Hutchesson, AC; Jones, AF; Moran, A | 1 |
| Carmena, R | 1 |
| Arizon, JM; Blanco, J; Concha, M; Espino, A; Hidalgo, L; Jimenez-Pereperez, JA; Lopez-Miranda, J; Perez-Jimenez, F; Valles, F; Zambrana, JL | 1 |
| Dibirov, AD; Gavrilov, SG; Kolesnikov, AL; Kostrub, VV; Kulikov, VM; Kuznetsov, MR; Petukhov, VA; Savel'ev, SV; Sergeeva, NA; Zubarev, AP | 1 |
| Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Herings, RM; Leufkens, HG; Urquhart, J | 1 |
| Boccuzzi, SJ; Cedarholm, JC; DeMaio, SJ; Ivanhoe, R; King, SB; Klein, JL; Kosinski, AS; Stillabower, ME; Talley, JD; Weintraub, WS | 1 |
| Bren, AF; Kandus, A; Koselj, M; Kovac, D; Kveder, R | 1 |
| Kłosiewicz-Latoszek, L; Nowicka, G; Szostak, WB | 1 |
| Gørbitz, C; Malt, UF; Ose, L; Tonstad, S | 1 |
| Keane, WF | 1 |
| Alonso-Pulpón, L; Anguita, M; Arizón, JM; Vallés, F | 1 |
| Correia, AM; Miguel, MJ; Nogueira, AC; Pinto, JR; Prata, MM; Rodrigues, MC; Vicente, O | 1 |
| Jacobs, RH; Lal, SM; Nolph, KD | 1 |
| Hoeg, JM; Nelson, LM; Robins, ED | 1 |
| de Alava, E; Lozano, MD; Pardo-Mindán, FJ; Sola, JJ | 1 |
| Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M | 1 |
| Böhler, J; Eckardt, HG; Schollmeyer, P; Wanner, C; Wieland, H | 1 |
| Lu, ZL | 1 |
| Ciafone, R; Galen, M; Knoll, RW | 1 |
| Neugarten, J; Rubin, R; Sablay, L; Silbiger, S | 1 |
| Carrier, M; Cartier, R; Genest, J; Leclerc, Y; Pelletier, GB; Pelletier, LC | 1 |
| Kasiske, BL; Keane, WF; Kim, Y; O'Donnell, MP; Schmitz, PG | 1 |
| Hall, IH; Reynolds, DJ; Simlot, R; Wong, OT | 1 |
| Barth, JD | 1 |
| Martinez Hernandez, BE; Moorhead, JF; Persaud, JW; Varghese, Z | 1 |
| Cimino, R; Civardi, F; Maltagliati, L; Marangoni, R; Masi, F; Romei Longhena, G | 1 |
| Antoniou, S; Dimitriadis, A; Hatzisavvas, N; Kaldi, I; Pastore, F; Stangou, M | 1 |
| Bennett, MJ; Coates, PM; Cortner, JA; Le, NA | 1 |
| Hunninghake, DB; Knutson, KR; Kubo, SH; Olivari, MT; Peters, JR | 1 |
| Martínez-Castelao, A | 1 |
| Dobs, AS; Goldberg, A; Guccione, M; Hoover, DR; Prasad, M | 1 |
| Abdul-Ghaffar, NU; el-Sonbaty, MR | 1 |
| Feingold, KR; Marcelino, JJ | 1 |
| Coleman, JE; Watson, AR | 1 |
| Poledne, R; Stejskalová, A; Stípek, S; Tĕmínová, J; Tesar, V; Zima, T | 1 |
| Wray, R | 1 |
| Simons, LA | 1 |
| Bjerve, KS; Carlsen, SM; Følling, I; Rossvoll, O | 1 |
| Chacón, P; Piera, LL; Segarra, A; Vilardell, M | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Branchi, A; Fiorenza, AM; Gandini, R; Maraffi, F; Rovellini, A; Sommariva, D | 1 |
| Etti, H; Kondor, P; Pirich, C; Sinzinger, H | 1 |
| Lüscher, TF; Noll, G; Tanner, FC | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Anguita Sánchez, M; Blanco Cerrada, J; Casares Mediavilla, J; Jiménez Perepérez, JA; López Miranda, J; Muñoz Carvajal, I; Pérez Jiménez, F; Vallés Belsúe, F; Zambrana García, JL | 1 |
| Johannesson, M; Jönsson, B | 1 |
| Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC | 1 |
| O'Connor, PJ; Rush, WA; Trence, DL | 1 |
| Isley, W; Rajeshawari, M; Tal, A | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Buchalter, M | 1 |
| Durrington, P | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Albers, JJ; Bardsley, J; Brown, BG; Dowdy, A; Hillger, LA; Knopp, RH; Maher, VM; Poulin, D; Zhao, XQ | 1 |
| Kaysen, GA; Neverov, NI; Tareyeva, IE | 1 |
| Cuchel, M; Dolnikowski, GG; Jones, PJ; Lichtenstein, AH; Millar, JS; Schaefer, EJ; Vergani, C | 1 |
| Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M | 1 |
| Castro, P; Concha, M; Jimenéz-Perepérez, JA; López-Miranda, J; Montilla, P; Pérez-Jiménez, F; Vallés, F; Velasco, F; Zambrana, JL | 1 |
| Berg, KJ; Cheng, H; Forfang, K; Geiran, O; Gullestad, L; Høstmark, A; Ihlen, H; Nordal, KP; Schwartz, MS; Simonsen, S | 1 |
| Heidinger, K; Jovin, IS; Muller-Berghaus, G; Taborski, U | 1 |
| Sterna, R | 1 |
| Malik, AZ; Vlay, SC | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Berglund, L; Galeano, NF; Ginsberg, HN; Khouw, AS; Ramakrishnan, R; Witztum, JL | 1 |
| Guanci, R; Lilley, LL | 1 |
| Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D | 1 |
| Bren, AF; Buturović, J; Cerne, D; Kandus, A; Kaplan-Pavlovcic, S; Koselj, M; Kovac, D; Kveder, R; Lindic, J; Ponikvar, R | 1 |
| Mabuchi, H | 1 |
| Anand, R; Burrows, L; Genyk, Y; Knight, R; Moran, V; Schwartz, B | 1 |
| Davignon, J; Farnier, M | 1 |
| Luc, G | 1 |
| Christians, U; Floren, LC; Jacobsen, W | 1 |
| Chan, DC; Chow, CC; Cockram, CS; Ko, GT; Lam, CW; Mak, TW; Tsang, LW; Yeung, VT | 1 |
| Gholami, K; Maleki, M; Shafiee, A; Tavakoli, N | 1 |
| Arizón, JM; Blanco, A; Concha, M; Jansen, S; Jimenéz-Perepérez, JA; López-Miranda, J; Paniagua, JA; Pérez-Jiménez, F; Zambrana, JL | 1 |
| Fuh, MM; Hung, YJ; Jeng, C; Kuo, SW; Pei, D; Wu, DA | 1 |
| Barradell, LB; Goa, KL; McTavish, D | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Guo, J; Kou, W; Lu, Z | 1 |
| Farnier, M | 1 |
| El-Swefy, S; El-Sweidy, M; Meydani, M; Ordovas, JM; Schaefer, EJ; Seman, LJ; Sevanian, A; Smith, DE; van Dongen, D | 1 |
| Gotto, AM | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Hjermann, I; Tonstad, S | 1 |
| Fugit, RV; Resch, ND | 1 |
| Whitney, E | 1 |
| Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A | 1 |
| Malminiemi, K; Malminiemi, O; Palomäki, A | 1 |
| Bergeron, J; Frohlich, J; Sniderman, AD | 1 |
| Brun, JM | 1 |
| Caillard, S; Moulin, B | 1 |
| Vergès, B | 1 |
| Turpin, G | 1 |
| Pearson, TA | 1 |
| Chen, X; Hu, P; Huang, D; Huang, M; Xie, M; Yu, Y; Zhang, H | 1 |
| Schwartz, JB | 1 |
| Le, NA | 1 |
| Bazalo, GR | 1 |
| Platts, J | 1 |
| Champion, KM; Furst, BA; Pierre, JM; Wirshing, DA; Wirshing, WC | 1 |
| Bays, HE; Berra, K; Favrot, LK; Guyton, JR; Harper, WL; Kashyap, ML; Kerzner, B; Kwiterovich, PO; McGovern, ME; Nash, SD; Simmons, PD; Toth, PD | 1 |
| Stein, EA | 1 |
| Mach, F | 1 |
| Taskinen, MR | 1 |
| Seed, M | 1 |
| Endo, A; Kuroda, M; Tanzawa, K; Tsujita, Y | 1 |
| Franz, M; Klauser, R; Kovarik, J; Pidlich, H; Pohanka, E; Reading, S; Traindl, O; Watschinger, B; Widhalm, K | 1 |
| Idzior-Waluś, B | 1 |
| Chan, PC; Cheng, IK; Robinson, JD; Tsang, MT; Yeung, HW; Yeung, WC | 1 |
| Falger, S; Franz, M; Gisinger, J; Klauser, R; Kovarik, J; Reading, S; Traindl, O; Widhalm, K | 1 |
| Toyota, T | 1 |
| Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW | 1 |
| Chrysanthopoulos, C; Kounis, N | 1 |
| Angelé, B; Bellinghieri, G; Savica, V | 1 |
| Ballantyne, CM; Chandler, L; Cocanougher, B; Farmer, JA; Frazier, OH; Gotto, AM; Jones, PH; Payton-Ross, C; Radovancevic, B; Young, JB | 1 |
| Foo, WM; Lim, MC | 1 |
| Beigel, Y; Davidson, E; Fuchs, J; Green, P; Rotenberg, Z; Weinberger, I; Zlotikamien, B | 1 |
| Illingworth, DR | 1 |
| Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE | 1 |
| Dardamanis, M; Elisaf, M; Pappas, M; Sferopoulos, G; Siamopoulos, KC | 1 |
| Grundy, SM; Vega, GL | 3 |
| Harris, DC; Mitchell, P; Simons, LA; Stewart, JH | 1 |
| Szamosi, A | 1 |
| D'Amico, G; Gentile, MG | 1 |
| Camps, J; Joven, J; Masana, L; Simó, JM; Turner, PR; Vilella, E; Villabona, C | 1 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Halstenson, CE; Kasiske, BL; Keane, WF; La Belle, P; Langendörfer, A; Velosa, JA | 1 |
| Larson, KK; Marais, GE | 1 |
| McQueen, MJ | 1 |
| Arad, Y; Ginsberg, HN; Ramakrishnan, R | 1 |
| Joven, J; Masana, L; Turner, PR; Vilella, E | 1 |
| Galbraith, W; Watt, G | 1 |
| Abrignani, MG; Alaimo, G; Averna, MR; Barbagallo, CM; Davì, G; Marino, G; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Brown, WV | 1 |
| La Ville, AE; Lewis, B; Rowles, PM; Seddon, AM; Shaikh, M; Woolf, N | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM; van 't Laar, A | 1 |
| Erkelens, DW; Hené, RJ; Joles, JA; Koomans, HA; Rabelink, AJ | 1 |
| Heel, RC; Henwood, JM | 1 |
| Ballantyne, CM; DeBakey, ME; Gotto, AM; Jones, PH; Noon, GP; Patsch, W; Payton-Ross, C; Short, HD; Young, JB | 1 |
| Garvis, WJ; Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
| Cleary, MP; Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
| Carew, TE; Parthasarathy, S; Steinberg, D | 1 |
| Feeman, WE | 1 |
| Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Carew, TE; Schwenke, DC; Steinberg, D | 1 |
| Perry, RS | 1 |
| Bilheimer, DW; Cuthbert, JA; East, CA; Lipsky, PE | 1 |
37 review(s) available for lovastatin and Hyperlipemia
| Article | Year |
|---|---|
Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review.
Topics: Anticholesteremic Agents; Atherosclerosis; Biological Products; Cholesterol; Cholesterol, LDL; Dietary Supplements; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin | 2023 |
Biotechnological Production of Statins: Metabolic Aspects and Genetic Approaches.
Topics: Animals; Biotechnology; Fermentation; Fungi; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Metabolic Engineering; Pravastatin | 2019 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Update on the management of dyslipidemia.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Humans; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Assessment; Risk Factors | 2002 |
Management of dyslipidemia in the primary prevention of coronary heart disease.
Topics: Animals; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2002 |
Niacin extended-release/lovastatin: combination therapy for lipid disorders.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin | 2002 |
Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
What's new in lipid management?
Topics: Bile Acids and Salts; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lovastatin; Niacin | 2003 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
Lipids and the kidney.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Blood Pressure; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lovastatin; Male; Proteinuria | 1994 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Arginine; Arteriosclerosis; Coronary Vessels; Endothelin-1; Endothelium, Vascular; Humans; Hyperlipidemias; Lipids; Lipoproteins, LDL; Lovastatin; Nitric Oxide; Swine | 1996 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Current and future treatment of hyperlipidemia: the role of statins.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?
Topics: Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Immunosuppressive Agents; Lovastatin; Naphthalenes; Organ Transplantation | 1998 |
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
Topics: Coronary Disease; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Military Personnel; Nutrition Surveys; Randomized Controlled Trials as Topic; Risk Factors; Texas | 2000 |
[Kidney and statins].
Topics: Arteriosclerosis; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Kidney Failure, Chronic; Lovastatin | 2001 |
[Statins and diabetic hyperlipidemia].
Topics: Cholesterol, HDL; Diabetes Complications; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Triglycerides | 2001 |
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lovastatin; Niacin | 2000 |
Lipid-lowering medications: what the new guidelines and data mean to women.
Topics: Age Factors; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Practice Guidelines as Topic; Pyrroles; Triglycerides | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Diabetic dyslipidemia.
Topics: Apolipoproteins; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lovastatin; Prevalence; Risk Factors | 2002 |
The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
Topics: Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lovastatin; Postmenopause; Primary Prevention; Randomized Controlled Trials as Topic; Risk Factors | 2002 |
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lipid Metabolism; Lipoprotein Lipase; Lovastatin; Postoperative Complications; Risk Factors | 1992 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.
Topics: Humans; Hyperlipidemias; Lovastatin | 1988 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol | 1986 |
64 trial(s) available for lovastatin and Hyperlipemia
| Article | Year |
|---|---|
Effectiveness and safety of red yeast rice predominated by monacolin K β-hydroxy acid form for hyperlipidemia treatment and management.
Topics: Biological Products; Cholesterol, LDL; Humans; Hydroxy Acids; Hypercholesterolemia; Hyperlipidemias; Lovastatin | 2022 |
A Randomized Clinical Efficacy Trial of Red Yeast Rice (Monascus pilosus) Against Hyperlipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Monascus; Phytotherapy; Time Factors; Treatment Outcome; Triglycerides | 2019 |
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein B-100; Apolipoprotein B-48; Cholesterol, HDL; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Lipid Metabolism; Lovastatin; Male; Middle Aged; Niacin; Treatment Outcome; Triglycerides | 2008 |
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Topics: Adult; Apolipoproteins B; Cross-Over Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 2002 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
Topics: Analysis of Variance; Chi-Square Distribution; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Niacin; Probability; Sensitivity and Specificity; Treatment Outcome | 2003 |
Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Alcohols; Female; Humans; Hyperlipidemias; Lipid Metabolism; Lipid Peroxidation; Lipids; Lovastatin; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2002 |
Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cholesterol, Dietary; Diet, Atherogenic; Diet, Vegetarian; Dietary Fiber; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Male; Middle Aged | 2003 |
Hormonal changes with cholesterol reduction: a double-blind pilot study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Pyrroles | 2004 |
Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
Topics: Administration, Oral; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Hyperlipidemias; Liver Function Tests; Lovastatin; Male; Middle Aged; Muscular Diseases; Niacin; Patient Compliance; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, Dietary; Cholesterol, LDL; Cross-Over Studies; Dietary Fiber; Drug Therapy, Combination; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Phytosterols; Primary Prevention; Soybean Proteins; Treatment Outcome | 2005 |
Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.
Topics: Adult; Cholesterol; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppression Therapy; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine.
Topics: Adolescent; Adult; Cyclosporine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Niacin; Postoperative Complications; Prospective Studies; Triglycerides; Uric Acid | 1995 |
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Topics: Apolipoproteins; Apolipoproteins B; Cholesterol, LDL; Double-Blind Method; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Kinetics; Lipids; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Placebos; Triglycerides | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Blood Component Removal; Chemical Precipitation; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Extracorporeal Circulation; Female; Gemfibrozil; Heparin; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins, LDL; Lovastatin; Male | 1995 |
Early response of hyperlipidemic subjects to simvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Probucol; Renal Dialysis; Simvastatin | 1994 |
Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients.
Topics: Bezafibrate; Female; Heart Transplantation; Humans; Hyperlipidemias; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Prospective Studies | 1995 |
The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Topics: Adult; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Probucol; Regional Blood Flow; Simvastatin; Vitamin E | 1994 |
Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
Topics: Angioplasty, Balloon, Coronary; Cholesterol, HDL; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome | 1994 |
Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Hyperlipidemias; Kidney Transplantation; Lovastatin; Male; Middle Aged | 1994 |
[A comparison between lovastatin and pravastatin--effects on lipids, sleep and quality of life in primary hyperlipidemia].
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Quality of Life; Sleep | 1994 |
Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Lipoproteins; Long-Term Care; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Patient Acceptance of Health Care; Prospective Studies; Proteinuria; Triglycerides | 1994 |
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1994 |
Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Simvastatin | 1994 |
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin; Single-Blind Method; Triglycerides | 1993 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Double-Blind Method; Humans; Hyperlipidemias; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1995 |
Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.
Topics: Blood Glucose; Body Weight; Combined Modality Therapy; Coronary Disease; Diet; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipids; Lovastatin; Male; Metformin; Middle Aged; Prospective Studies | 1996 |
Prospective case control study to determine the effect of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure.
Topics: Adult; Case-Control Studies; Follicle Stimulating Hormone; Humans; Hydrocortisone; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipids; Lovastatin; Luteinizing Hormone; Male; Middle Aged; Nephrotic Syndrome; Prospective Studies; Testosterone | 1996 |
Atherogenic risk reduction in patients with dyslipidaemia. comparison between bezafibrate and lovastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Prospective Studies; Risk Factors | 1995 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
[A comparison of bezafibrate and lovastatin treatment at the usual doses in post-heart transplant hyperlipemia].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cross-Over Studies; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Postoperative Complications | 1996 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome; Triglycerides | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
Topics: Cholesterol, LDL; Colestipol; Cross-Over Studies; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance | 1997 |
Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Chronic Disease; Creatinine; Diet, Fat-Restricted; Disease Progression; Female; Glomerulonephritis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lipoproteins; Lovastatin; Male; Middle Aged; Proteinuria | 1997 |
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Humans; Hyperlipidemias; Lipoproteins; Lovastatin; Male; Middle Aged | 1997 |
Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in hyperlipemic heart transplant patients.
Topics: Bezafibrate; Cross-Over Studies; Female; Fibrinogen; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Lovastatin; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies | 1997 |
[The effect of hypolipemic treatment on the pharmacokinetics of propranolol].
Topics: Administration, Oral; Anticholesteremic Agents; Bezafibrate; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Hydroxylation; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Phenotype; Propranolol; Triglycerides | 1997 |
Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gingival Hyperplasia; Hirsutism; Humans; Hyperlipidemias; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lovastatin; Male; Middle Aged; Pravastatin; Tacrolimus | 1998 |
Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines | 1998 |
Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Time Factors; Triglycerides | 1998 |
Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
Topics: Bezafibrate; Cross-Over Studies; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Prospective Studies | 1998 |
[Effect of xuezhikang on the treatment of primary hyperlipidemia].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1997 |
Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population.
Topics: Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Military Personnel; Nutrition Surveys; Randomized Controlled Trials as Topic; Risk Factors; Texas | 2000 |
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Genotype; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Lovastatin; Male; Middle Aged; Niacin; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Regression Analysis | 2001 |
Comparison of LDL trap assay to other tests of antioxidant capacity; effect of vitamin E and lovastatin treatment.
Topics: Amidines; Anticholesteremic Agents; Antioxidants; Copper Sulfate; Coronary Disease; Cross-Over Studies; Double-Blind Method; Humans; Hyperlipidemias; Lipoproteins, LDL; Lovastatin; Male; Oxidants; Oxidation-Reduction; Reproducibility of Results; Sensitivity and Specificity; Vitamin E | 2000 |
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Lovastatin; Male; Middle Aged; Niacin; Risk Factors; Survival Analysis; Treatment Outcome | 2002 |
Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria.
Topics: Adult; Aged; Drug Tolerance; Female; Glomerulonephritis; Humans; Hyperlipidemias; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; Rhabdomyolysis | 1992 |
Big platelets in hyperlipidemic patients.
Topics: Aged; Blood Platelets; Coronary Disease; Double-Blind Method; Female; Fish Oils; Humans; Hyperlipidemias; Infant, Newborn; Lovastatin; Male; Middle Aged; Risk Factors; Triglycerides | 1992 |
[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Triglycerides | 1991 |
[Angiographic regression of coronary atheromatosis].
Topics: Angiography; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Niacin; Remission Induction | 1991 |
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lovastatin; Nephrotic Syndrome; Probucol | 1991 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Evaluation; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Phenols; Probucol; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Management of primary mixed hyperlipidemia with lovastatin.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Triglycerides | 1990 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Random Allocation; Simvastatin | 1988 |
138 other study(ies) available for lovastatin and Hyperlipemia
| Article | Year |
|---|---|
Bis[3-(4'-substituted phenyl)prop-2-ene]disulfides as a new class of antihyperlipidemic compounds.
Topics: Animals; Body Weight; Disulfides; Dose-Response Relationship, Drug; Eating; Hyperlipidemias; Hypolipidemic Agents; Male; Propane; Rats; Rats, Wistar; Structure-Activity Relationship | 2004 |
Discovery and synthesis of novel substituted benzocoumarins as orally active lipid modulating agents.
Topics: Animals; Benzene; Cholesterol; Cholesterol, HDL; Coumarins; Cricetinae; Hyperlipidemias; Hypolipidemic Agents; Schiff Bases; Triglycerides | 2011 |
Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules.
Topics: Administration, Oral; Animals; Carboxylesterase; Cell Line, Tumor; Down-Regulation; Drugs, Chinese Herbal; Humans; Hyperlipidemias; Inflammation; Isoflavones; Lovastatin; Male; Mice, Inbred C57BL; Pregnane X Receptor; Up-Regulation | 2018 |
Formulation design and evaluation of a self-microemulsifying drug delivery system of lovastatin.
Topics: Animals; Biological Availability; Chemical Phenomena; Drug Compounding; Drug Delivery Systems; Drug Stability; Drug Storage; Emulsions; Excipients; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Male; Rats; Rats, Wistar; Solubility; Surface Properties; Surface-Active Agents; Temperature | 2012 |
Hypolipidemic and antioxidant activities of polysaccharides from Rosae Laevigatae Fructus in rats.
Topics: Animals; Antioxidants; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Fruit; Gene Expression; Glutathione Peroxidase; Hydrogen Bonding; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein Lipase; Liver; Lovastatin; Male; Malondialdehyde; Molecular Weight; Polysaccharides; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosaceae; Superoxide Dismutase | 2013 |
Effect of 7-difluoromethyl-5, 4'-dimethoxygenistein on aorta atherosclerosis in hyperlipidemia ApoE(-/-) mice induced by a cholesterol-rich diet.
Topics: Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Genistein; Hyperlipidemias; Lipids; Lovastatin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitrites; Vasodilation; von Willebrand Factor | 2013 |
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Topics: Animals; Anticholesteremic Agents; Cholesterol, LDL; Disease Models, Animal; Hyperlipidemias; Liver; Lovastatin; Male; Nephrotic Syndrome; Rats; Rats, Sprague-Dawley; Receptors, LDL; Triglycerides | 2014 |
Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.
Topics: Cell Proliferation; Cohort Studies; Disease-Free Survival; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Likelihood Functions; Lovastatin; Ovarian Neoplasms; Retrospective Studies | 2014 |
¹H-NMR and MS based metabolomics study of the intervention effect of curcumin on hyperlipidemia mice induced by high-fat diet.
Topics: Animals; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Curcuma; Curcumin; Diet, High-Fat; Dietary Fats; Discriminant Analysis; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Liver; Lovastatin; Magnetic Resonance Spectroscopy; Male; Metabolic Networks and Pathways; Metabolome; Mice; Mice, Inbred C57BL; Tandem Mass Spectrometry; Triglycerides | 2015 |
Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Berberine; Cholesterol; Cholesterol, LDL; Cricetinae; Diet, High-Fat; Dietary Fats; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; gamma-Glutamyltransferase; Hyperlipidemias; Lovastatin; Male; Mesocricetus; RNA, Messenger; Time Factors; Triglycerides | 2015 |
Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.
Topics: Administration, Oral; Animals; Biological Availability; Biomarkers; Chemistry, Pharmaceutical; Cholesterol; Cholesterol, HDL; Disease Models, Animal; Drug Carriers; Drug Stability; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Models, Chemical; Nanoparticles; Rats, Wistar; Solubility; Technology, Pharmaceutical | 2015 |
Hypolipidemic effects of Monascus-fermented soybean extracts in rats fed a high-fat and -cholesterol diet.
Topics: Animals; Cholesterol, Dietary; Dietary Fats; Fermentation; Glycine max; Hyperlipidemias; Hypolipidemic Agents; Isoflavones; Lipids; Liver; Lovastatin; Male; Monascus; Phytotherapy; Plant Extracts; Rats | 2009 |
Red mold rice promotes neuroprotective sAPPalpha secretion instead of Alzheimer's risk factors and amyloid beta expression in hyperlipidemic Abeta40-infused rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Brain; Cerebral Ventricles; Cholesterol; Fungi; Humans; Hyperlipidemias; Infusions, Intravenous; Learning Disabilities; Lovastatin; Male; Maze Learning; Memory Disorders; Monascus; Oryza; Peptide Fragments; Rats; Rats, Wistar; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances | 2010 |
SR-PSOX at sites predisposed to atherosclerotic lesion formation mediates monocyte-endothelial cell adhesion.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Adhesion; Cells, Cultured; Chemokine CXCL16; Chemokines, CXC; Coculture Techniques; Cytokines; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Inflammation Mediators; Lovastatin; Macrophages; Monocytes; Rabbits; Receptors, Scavenger; Thiazolidinediones | 2011 |
Trillin, a steroidal saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress.
Topics: 1-Butanol; Animals; Antioxidants; Blood Coagulation; Diet, High-Fat; Dioscorea; Disease Models, Animal; Drugs, Chinese Herbal; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Lovastatin; Male; Malondialdehyde; Oxidative Stress; Phytotherapy; Rats; Rats, Sprague-Dawley; Rhizome; Saponins; Solvents; Superoxide Dismutase | 2012 |
Hypolipidemic effects of kaempferide-7-O-(4''-O-acetylrhamnosyl)-3-O-rutinoside in hyperlipidemic rats induced by a high-fat diet.
Topics: Actinidia; Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Enzyme Activation; Glycosides; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Kaempferols; Lovastatin; Male; Phosphatidate Phosphatase; Plant Extracts; Plant Leaves; Rats; Rats, Wistar; Triglycerides | 2012 |
Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia.
Topics: Animals; Cholesterol; Combined Modality Therapy; Cricetinae; Dioscorea; Fermentation; Functional Food; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Lovastatin; Male; Mesocricetus; Monascus; Rhabdomyolysis; Triglycerides | 2012 |
[Effect of monascus on improving the hemorheology of rats with high blood lipids].
Topics: Animals; Anticholesteremic Agents; Blood Viscosity; Fermentation; Hemorheology; Hyperlipidemias; Lovastatin; Male; Random Allocation; Rats; Rats, Wistar; Triticum | 2001 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin | 2003 |
Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis.
Topics: Animals; Blotting, Western; Cholesterol, Dietary; Electron Spin Resonance Spectroscopy; Farnesol; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Mevalonic Acid; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Superoxides | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
A Consumer Use Study of Over-The-Counter lovastatin (CUSTOM).
Topics: Anticholesteremic Agents; Cholesterol, LDL; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Nonprescription Drugs; Self Administration; Self Care | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
[Effect of Laminaria japonica polysaccharides on lowing serum lipid and anti-atherosclerosis in hyperlipemia quails].
Topics: Animals; Arteriosclerosis; Body Weight; Hyperlipidemias; Hypolipidemic Agents; Laminaria; Lipids; Lovastatin; Male; Plants, Medicinal; Polysaccharides; Quail | 2005 |
Inhibitory effect of Magnolia officinalis and lovastatin on aortic oxidative stress and apoptosis in hyperlipidemic rabbits.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Aorta, Thoracic; Apoptosis; Caspase 8; Caspase 9; Caspases; Cholesterol; Deoxyguanosine; Fas Ligand Protein; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Magnolia; Malondialdehyde; Membrane Glycoproteins; Oxidative Stress; Plant Extracts; Rabbits; Tumor Necrosis Factors | 2006 |
[Protective effect of effective parts of Zingiber Offecinal on vascular endothelium of the experimental hyperlipidemic rats].
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Drugs, Chinese Herbal; Endothelium, Vascular; Hyperlipidemias; Interleukin-6; Lovastatin; Male; Plants, Medicinal; Rats; Rats, Wistar; Rhizome; Tumor Necrosis Factor-alpha; Zingiberaceae | 2006 |
Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Topics: Apolipoproteins E; Cholesterol; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Simvastatin; Treatment Outcome | 2007 |
Effect of Monascus purpureus-fermented rice on lipidemia and fatty liver in quail.
Topics: Animals; Anticholesteremic Agents; Biological Products; Cholesterol; Dose-Response Relationship, Drug; Fatty Liver; Hyperlipidemias; Lovastatin; Monascus; Phytotherapy; Quail; Triglycerides | 2006 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Sterol biosynthesis: effect of compactin and its derivatives.
Topics: Animals; Cholesterol; Dogs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Naphthalenes; Rabbits; Rats | 1983 |
Management of patients with dyslipidaemia.
Topics: Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
[Antihyperlipidemic actions in the treatment of nephropathies].
Topics: Adolescent; Adult; Aged; Chronic Disease; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Lovastatin; Male; Middle Aged; Remission Induction | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Cohort Studies; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol > 160 mg/dl.
Topics: Aged; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Pilot Projects; Treatment Outcome | 1995 |
Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data.
Topics: Absenteeism; Adult; Cohort Studies; Depression; Diet, Fat-Restricted; Female; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Prevalence; Risk Factors; Simvastatin; Surveys and Questionnaires | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1995 |
Lovastatin ameliorates depressed intraglomerular proteolytic activities in experimental nephrotic syndrome.
Topics: Albuminuria; Animals; Doxorubicin; Endopeptidases; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Kidney Glomerulus; Lovastatin; Male; Nephrotic Syndrome; Proteinuria; Rats; Rats, Inbred Lew | 1994 |
Descriptive study of lipid-modulating drug use in a French professional population.
Topics: Adult; Cross-Sectional Studies; Female; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Simvastatin; Thyroid Diseases | 1994 |
Effect of lovastatin and bezafibrate on cyclosporine-induced hyperlipidemia in rabbits.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Hyperlipidemias; Kinetics; Lipoproteins; Lovastatin; Rabbits; Triglycerides | 1995 |
Hyperlipidemia in renal transplant recipients: does it matter and can we treat it?
Topics: Adult; Female; Graft Occlusion, Vascular; Humans; Hyperlipidemias; Kidney Transplantation; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Simvastatin | 1995 |
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
[Correction of hyperlipidemia in patients with gallstones as a method of improving results of extracorporeal lithotripsy].
Topics: Cholelithiasis; Humans; Hyperlipidemias; Lithotripsy; Lovastatin | 1994 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1994 |
[Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
Topics: Adult; Aged; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1993 |
[The use of lovastatin in patients with hyperlipemia following heart transplantation treated with cyclosporine].
Topics: Cyclosporine; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Rhabdomyolysis | 1994 |
Hyperlipidemia in renal transplant recipients: natural history and response to treatment.
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1994 |
Lipid-lowering effects of lovastatin in CAPD patients.
Topics: Aged; Cholesterol; Female; Humans; Hyperlipidemias; Lipids; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Retrospective Studies; Triglycerides | 1993 |
Aberrant hypothalamic-pituitary-ovarian axis in the Watanabe heritable hyperlipidemic rabbit.
Topics: Animals; Cholesterol; Estradiol; Female; Fertility; Follicle Stimulating Hormone; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypothalamo-Hypophyseal System; Lovastatin; Luteinizing Hormone; Male; Ovary; Progesterone; Rabbits; Receptors, LDL; Simvastatin; Sperm-Ovum Interactions | 1994 |
Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants.
Topics: Acute Kidney Injury; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Leprostatic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1994 |
Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil.
Topics: Acute Kidney Injury; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1993 |
Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis.
Topics: Animals; Antihypertensive Agents; Cholesterol; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Hypertension; Lovastatin; Male; Rats; Rats, Sprague-Dawley | 1994 |
Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation.
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cholesterol, LDL; Coronary Disease; Female; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin; Survival Analysis | 1994 |
Lovastatin retards the progression of established glomerular disease in obese Zucker rats.
Topics: Animals; Cell Division; Cells, Cultured; Glomerular Mesangium; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Lovastatin; Male; Obesity; Rats; Rats, Zucker; Time Factors | 1993 |
Comparison between 6,7-dihydro-5H-dibenz(c,e)azepine and lovastatin as hypolipidemic agents in rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Cholesterol; Dibenzazepines; Enzymes; Hyperlipidemias; Lovastatin; Male; Phospholipids; Rats; Rats, Sprague-Dawley; Triglycerides | 1993 |
Treatment of and screening for hyperlipidemia.
Topics: Arteriosclerosis; Combined Modality Therapy; Humans; Hyperlipidemias; Lovastatin | 1993 |
Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis.
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Retrospective Studies; Simvastatin; Uremia | 1993 |
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 1993 |
The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia.
Topics: Adult; Apolipoproteins B; Glycine; Heparin; Humans; Hyperlipidemias; Lipase; Lipolysis; Lipoproteins, VLDL; Liver; Lovastatin; Male; Middle Aged | 1993 |
Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin.
Topics: Female; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 1993 |
Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy.
Topics: Acute Disease; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Pancreatic Pseudocyst; Pancreatitis; Rhabdomyolysis | 1995 |
Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Male; Middle Aged; Patient Selection; Pravastatin; Retrospective Studies; Treatment Outcome | 1996 |
Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.
Topics: Adolescent; Child; Child, Preschool; Cholesterol; Combined Modality Therapy; Creatinine; Diet; Drug Resistance; Enzyme Inhibitors; Feeding Behavior; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Infant; Lovastatin; Male; Nephrotic Syndrome; Retrospective Studies; Serum Albumin; Simvastatin; Triglycerides | 1996 |
[The effect of lovastatin on the development of adriamycin nephropathy in rats].
Topics: Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Doxorubicin; Hyperlipidemias; Lipids; Lovastatin; Male; Nephrotic Syndrome; Rats; Rats, Wistar; Serum Albumin | 1995 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Disease; Diet; Factor VII; Humans; Hyperlipidemias; Lovastatin; Risk Factors; Simvastatin; Smoking | 1995 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Sweden | 1996 |
The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Apoproteins; Cholesterol, HDL; Diet, Fat-Restricted; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Cost-Benefit Analysis; Drug Monitoring; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Survival Rate | 1997 |
Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Follow-Up Studies; Health Maintenance Organizations; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Midwestern United States; Niacin; Patient Compliance; Triglycerides | 1997 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin | 1997 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Myocardial Ischemia; Risk Factors; Simvastatin | 1997 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Female; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Immunosuppressive Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Lung Transplantation; Male; Middle Aged; Myocardial Ischemia; Probucol; Radionuclide Angiography; Retrospective Studies; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1997 |
Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Heart Transplantation; Humans; Hyperlipidemias; Incidence; Lovastatin; Male; Middle Aged; Time Factors; Treatment Outcome | 1997 |
Lipid-lowering with statins and fibrinolytic parameters.
Topics: Cholesterol, LDL; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Long-term patency (9 1/2 years) and atherosclerosis of a polytetrafluoroethylene (Gortex) coronary artery bypass graft.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Blood Vessel Prosthesis; Cardiac Catheterization; Cholesterol; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Hyperlipidemias; Lovastatin; Polytetrafluoroethylene; Prosthesis Failure | 1998 |
Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Topics: Anticholesteremic Agents; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Risk; United States | 1998 |
Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tr
Topics: Adult; Animals; Apolipoproteins B; Female; Guinea Pigs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kinetics; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Models, Theoretical; Receptors, LDL | 1998 |
Drug interaction triggers weakness.
Topics: Aged; Anti-Bacterial Agents; Anticholesteremic Agents; Drug Interactions; Erythromycin; Humans; Hyperlipidemias; Lovastatin; Male; Muscle Weakness; Respiratory Tract Infections; Rhabdomyolysis | 1998 |
Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Data Interpretation, Statistical; Drug Interactions; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic | 1998 |
Reducing expenditures for statin-type lipid-lowering agents.
Topics: Cost Control; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Managed Care Programs; United States | 1998 |
Therapy of hyperlipidemia with lovastatin in kidney transplant patients on cyclosporine A immunosuppression: three-year experience.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cyclosporine; Electromyography; Female; Follow-Up Studies; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Rhabdomyolysis | 1998 |
[Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?].
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Simvastatin | 1998 |
[Lipid lowering: myth or therapeutic necessity?].
Topics: Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Pyridines; Risk Factors | 1998 |
Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Leptin; Lovastatin; Male; Middle Aged; Obesity; Proteins | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured; Cricetinae; Diabetes Mellitus, Experimental; Disease Models, Animal; Foam Cells; Hyperlipidemias; Lipid Peroxidation; Lovastatin; Male; Mesocricetus; Probucol; Reference Values; Streptozocin; Vitamin E | 2000 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial.
Topics: Adult; Aged; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Risk Factors; Time Factors | 2000 |
Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic.
Topics: Aged; Ambulatory Care; Blood Glucose; Dose-Response Relationship, Drug; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Liver; Lovastatin; Male; New Mexico; Pharmacy Service, Hospital; Prospective Studies; Simvastatin | 2000 |
The Air Force/Texas Coronary Atherosclerosis Prevention Study: implications for preventive cardiology in the general adult US population.
Topics: Aged; Angina, Unstable; Cholesterol, LDL; Coronary Artery Disease; Death, Sudden, Cardiac; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic | 1999 |
Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.
Topics: Apolipoproteins B; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Monitoring; Humans; Hyperlipidemias; Lovastatin; Practice Patterns, Physicians'; Predictive Value of Tests | 2001 |
[Statins: a major therapeutic breakthrough].
Topics: Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin | 2001 |
[Practical questions for the expert].
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Menopause; Triglycerides | 2001 |
[Effects of lovastatin on plasma lipid, plasma glucose and insulin metabolism of patients with type II B hyperlipemia].
Topics: Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Lovastatin; Male; Middle Aged | 1999 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin.
Topics: Anticholesteremic Agents; Antipsychotic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dibenzothiazepines; Electrocardiography; Female; Humans; Hyperlipidemias; Long QT Syndrome; Lovastatin; Middle Aged; Mixed Function Oxygenases; Quetiapine Fumarate; Schizophrenia; Time Factors; Triglycerides | 2002 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals.
Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Feces; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Hyperlipidemias; Liver; Lovastatin; Male; Mice; Naphthalenes; Polyethylene Glycols; Rats; Species Specificity; Sterols | 1979 |
Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein (a).
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Kidney Transplantation; Lipoprotein(a); Lovastatin; Male; Middle Aged; Time Factors | 1992 |
[Influence of lovastatin on serum lipids in patients with primary hyperlipidemia phenotype IIa and IIb. I. Efficacy of lovastatin in the treatment of hyperlipoproteinemia].
Topics: Adolescent; Adult; Aged; Humans; Hyperlipidemias; Hyperlipoproteinemias; Lipids; Lovastatin; Male; Middle Aged; Phenotype | 1992 |
Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Female; Humans; Hyperlipidemias; Kidney Transplantation; Lipoprotein(a); Lovastatin; Male; Middle Aged; Postoperative Complications; Triglycerides | 1992 |
[Diabetes mellitus and hyperlipidemia].
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Pravastatin | 1992 |
[Clinical study of lipid metabolism disorders (discussion)].
Topics: Arteriosclerosis; Cholestyramine Resin; Diet; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Probucol; Risk Factors | 1992 |
Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine.
Topics: Adult; Cholestyramine Resin; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Male; Rhabdomyolysis | 1992 |
[Dyslipidemia in the uremic patient: the therapeutic role played by simvastatin].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Renal Dialysis; Simvastatin; Uremia | 1992 |
Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations.
Topics: Analysis of Variance; Drug Therapy, Combination; Follow-Up Studies; Heart Transplantation; Humans; Hyperlipidemias; Incidence; Lipids; Lovastatin; Postoperative Complications; Risk Factors; Texas; Time Factors | 1992 |
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Treatment of nephrotic hyperlipidemia with lovastatin.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Time Factors | 1991 |
Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia.
Topics: Apolipoproteins B; Cholesterol; Humans; Hyperlipidemias; Lipoproteins, LDL; Lovastatin; Male; Metabolism; Middle Aged; Single-Blind Method; Triglycerides | 1991 |
Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin.
Topics: Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1991 |
Toxicity of lovastatin in rats with experimentally induced nephrotic syndrome.
Topics: Animals; Cholesterol; Hyperlipidemias; Lovastatin; Male; Nephrotic Syndrome; Rats; Rats, Inbred Strains; Triglycerides | 1990 |
The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Female; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Nephrotic Syndrome | 1990 |
Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
Topics: Acute Kidney Injury; Biological Assay; Drug Interactions; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1990 |
Cholestatic jaundice associated with lovastatin (Mevacor) therapy.
Topics: Adult; Cholestasis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clinical Enzyme Tests; Follow-Up Studies; Humans; Hyperlipidemias; Lovastatin; Male; Time Factors; Triglycerides | 1990 |
Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Triglycerides | 1990 |
Lipid-lowering drugs in treatment of hyperlipidaemia associated with nephrotic syndrome.
Topics: Animals; Drug Evaluation, Preclinical; Hyperlipidemias; Lovastatin; Male; Nephrotic Syndrome; Random Allocation; Rats | 1989 |
Simvastatin in the media.
Topics: Advertising; Anticholesteremic Agents; Humans; Hyperlipidemias; Lovastatin; Simvastatin | 1989 |
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].
Topics: Aged; Cardiovascular Diseases; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Risk; Simvastatin | 1989 |
Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain.
Topics: Animals; Aorta; Arteriosclerosis; Hyperlipidemias; Lipids; Lipoproteins; Lovastatin; Rabbits | 1989 |
Cholesterol synthesis inhibitors in hyperlipidaemia.
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
Topics: Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Humans; Hyperlipidemias; Lipoproteins, VLDL; Lovastatin; Middle Aged; Nephrotic Syndrome; Triglycerides | 1988 |
Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin).
Topics: Adult; Anticholesteremic Agents; Cholesterol; Female; Heart Transplantation; Humans; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Male; Middle Aged; Naphthalenes; Postoperative Complications; Triglycerides | 1987 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Nephrons; Rats; Rats, Inbred Strains; Triglycerides | 1988 |
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats.
Topics: Albuminuria; Animals; Cholesterol; Clofibrate; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Lovastatin; Male; Obesity; Rats; Rats, Zucker; Triglycerides | 1988 |
In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
Topics: Animals; Arteriosclerosis; Depression, Chemical; Drug Evaluation, Preclinical; Foam Cells; Hyperlipidemias; Lipoproteins, LDL; Lovastatin; Macrophages; Oxidation-Reduction; Phenols; Probucol; Rabbits | 1988 |
Lovastatin.
Topics: Humans; Hyperlipidemias; Lovastatin | 1988 |
The role of lipids in progressive glomerular disease.
Topics: Animals; Clofibric Acid; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Hypertension, Renal; Lipid Metabolism; Lovastatin; Rats; Rats, Zucker | 1987 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipoproteins, LDL; Lovastatin; Phenols; Probucol; Rabbits | 1987 |
Detection of familial hypercholesterolemia by assaying functional low-density-lipoprotein receptors on lymphocytes.
Topics: Cells, Cultured; Cholesterol, LDL; Diagnosis, Differential; DNA; Female; Genetic Carrier Screening; Homozygote; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Lymphocyte Activation; Lymphocytes; Male; Methods; Naphthalenes; Receptors, LDL | 1986 |